Biotechnology company Regeneron buying 23andMe for $256 million
Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said that it was looking to sell “substantially all of its […]
